Braveheart Bio Reports Q2 2026 Results, Initiates Phase 3 LIONHEART-HCM Trial, Extends Cash Runway to 2029
BRVE sits 21% above its 52-week low of $24.305.
Summary
Braveheart Bio reported Q2 2026 results with $122.8M in cash ($527.3M pro forma for IPO), initiated its Phase 3 LIONHEART-HCM trial, and guided cash runway into 2029.
Key Events · Earnings and Guidance · BRVE
-
Phase 3 LIONHEART-HCM Trial Initiated
Braveheart Bio has initiated LIONHEART-HCM, a Phase 3 trial evaluating BHB-1893 against metoprolol in obstructive HCM. First patient dosing is expected in 2026, with interim analysis results expected in H2 2027.
-
Cash Runway Extended to 2029
Cash and cash equivalents were $122.8M as of June 30, 2026, or $527.3M as-adjusted for the $404.5M in net IPO proceeds. Management estimates this funds operations into 2029.
-
Q2 2026 Net Loss of $15.0M
Net loss was $15.0M for Q2 2026, up from $0.4M in Q2 2025. R&D expenses were $11.1M and G&A was $4.8M, reflecting advancement of BHB-1893 and public company readiness.
-
NOBLEHEART-HCM Phase 3 Planned for H1 2027
With an active U.S. IND, Braveheart Bio expects to initiate NOBLEHEART-HCM, a global Phase 3 trial in non-obstructive HCM, in the first half of 2027.
Analysis · BRVE · Life Sciences
Braveheart Bio's first quarterly report as a public company delivers three material updates: a Phase 3 trial for its lead drug BHB-1893 is now underway, cash runway extends into 2029 thanks to the August IPO, and the company has 90 million shares outstanding. The clinical milestone is the key driver — LIONHEART-HCM is the pivotal trial that will determine whether BHB-1893 can compete with Bristol Myers' Camzyos in obstructive HCM. The $527.3 million pro forma cash position removes near-term financing risk, but the $15 million quarterly net loss shows the burn rate is accelerating as the company scales its global Phase 3 program.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 29.9% of the 1944 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.15%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BRVE was trading at $29.41 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $24.31 to $32.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.